MedTrace Logo

A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart

NCT00887770 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2009-07-16

No results posted yet for this study

Summary

This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart. AZD5672 will be compared against a drug (moxifloxacin - a licensed antibiotic) known to have a detectable but safe change on the electrical conduction of the heart.

Conditions

Interventions

DRUG

AZD5672

12 x 50mg tablet, oral, single dose

DRUG

Moxifloxacin

1 x 400mg capsule, oral, single dose

DRUG

placebo

12 x matched to AZD5672 50 mg tablet

DRUG

AZD5672

3 x 50mg tablet, oral. single dose

DRUG

placebo

9 x matched to AZD5672 50mg tablet

DRUG

placebo

1 x matched to Moxifloxacin capsule

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Mark Layton · AstraZeneca R&D, Alderley Park, UK

  • Darren Wilbraham · Guys Drug Research Unit, Newcomen St, London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Completion
2009-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00887770 on ClinicalTrials.gov